Therapeutic Targeting of Isocitrate Dehydrogenase Mutant AML

Expert Opinion on Investigational Drugs - United Kingdom
doi 10.1080/13543784.2017.1317745
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Affinity Purification and Kinetic Analysis of Mutant Forms of Yeast NAD+-specific Isocitrate Dehydrogenase

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
1997English

The Phosphorylation of Isocitrate Dehydrogenase inEscherichia Coli

Biochemical Society Transactions
Biochemistry
1982English

Cancer Therapeutic Targeting Using Mutant–p53-Specific siRNAs

Oncogene
Cancer ResearchGeneticsMolecular Biology
2019English

Reversible Inactivation of Isocitrate Dehydrogenase inEscherichia Coli

Biochemical Society Transactions
Biochemistry
1982English

Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy Against AML

Cancer Discovery
Oncology
2019English

Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism

Frontiers in Endocrinology
EndocrinologyMetabolismDiabetes
2020English

The Equilibrium Constant of the Isocitrate Dehydrogenase Reaction

Biochemical Journal
1968English

2-Hydroxyglutarate (2-Hg); Isocitrate Dehydrogenase 1 (IDH1)

Science-Business eXchange
2013English

Mutation Analysis of Isocitrate Dehydrogenase in Acute Lymphoblastic Leukemia

Genetic Testing and Molecular Biomarkers
MedicineGenetics
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy